Revenue
2012
2013
2014
2015
2016
2017
2018
2019
WINDTREE THERAPEUTICS INC /DE/ (WINT)
Price—Loading quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2016
2017
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $198,000 | $1.8M | $1.5M | $2.0M | $987,000 | $2.8M | $388,000 | $195,000 | — | — |
| Research & development | $16.3M | $8.3M | $11.1M | $17.8M | $15.4M | $12.7M | $10.6M | $17.4M | $31.7M | $28.9M | $26.7M | $27.7M | $21.6M | $17.2M | $17.1M |
| Operating expenses | $26.1M | $20.6M | $41.3M | $77.3M | $30.3M | $25.1M | $18.0M | $24.0M | $40.1M | $40.8M | $46.1M | $44.9M | $38.0M | $25.1M | $25.5M |
| Operating income | −$26.1M | −$20.6M | −$41.3M | −$77.3M | −$30.3M | −$24.9M | −$16.2M | −$22.5M | −$38.0M | −$39.8M | −$43.3M | −$44.5M | −$37.8M | −$24.5M | −$25.5M |
| EBITDAderived | — | — | — | — | — | — | — | −$22.4M | −$37.8M | −$39.1M | −$42.4M | −$43.8M | −$36.7M | −$23.3M | −$24.0M |
| Net income | −$1.8M | −$20.3M | −$39.2M | −$67.6M | −$32.6M | −$27.5M | −$20.5M | −$18.4M | −$39.5M | −$55.2M | −$44.1M | −$45.2M | −$37.3M | −$21.0M | −$19.2M |
| Basic EPSper diluted share | -$104.35 | -$4,718.84 | -$62.23 | -$136.64 | -$2.08 | -$2.51 | -$7.74 | -$24.14 | -$4.74 | -$7.98 | -$7.28 | -$0.82 | -$0.95 | -$0.93 | -$1.65 |
| Diluted EPSper diluted share | — | — | — | -$2.73 | -$2.08 | -$2.51 | -$7.74 | -$24.14 | -$4.74 | -$7.98 | -$7.84 | -$0.82 | -$0.95 | -$0.93 | -$1.65 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 8, 2024Form 4 | Fraser CraigPresident and CEO | BuyCommon Stock | 5.4K | $0.91 | $4.9K | 8.6K |